- call +1-201-465-4211
- email sales@mrinsights.biz
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
Scope of the Report:
The worldwide market for Acute Myeloid Leukemia Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Acute Myeloid Leukemia Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
DC regimen
AVD Regimen
VCD regimen
Market Segment by Applications, can be divided into
Hospital
Clinic
Others
There are 15 Chapters to deeply display the global Acute Myeloid Leukemia Treatment market.
Chapter 1, to describe Acute Myeloid Leukemia Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Acute Myeloid Leukemia Treatment, with sales, revenue, and price of Acute Myeloid Leukemia Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Acute Myeloid Leukemia Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Acute Myeloid Leukemia Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Acute Myeloid Leukemia Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Acute Myeloid Leukemia Treatment Introduction
1.2 Market Analysis by Type
1.2.1 DC regimen
1.2.2 AVD Regimen
1.2.3 VCD regimen
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Ambit Biosciences Corporation
2.1.1 Business Overview
2.1.2 Acute Myeloid Leukemia Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Celgene Corporation
2.2.1 Business Overview
2.2.2 Acute Myeloid Leukemia Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celgene Corporation Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Cephalon
2.3.1 Business Overview
2.3.2 Acute Myeloid Leukemia Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Cephalon Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Clavis Pharma
2.4.1 Business Overview
2.4.2 Acute Myeloid Leukemia Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Clavis Pharma Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Eisai
2.5.1 Business Overview
2.5.2 Acute Myeloid Leukemia Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Eisai Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Genzyme Corporation
2.6.1 Business Overview
2.6.2 Acute Myeloid Leukemia Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Genzyme Corporation Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Sunesis Pharmaceuticals
2.7.1 Business Overview
2.7.2 Acute Myeloid Leukemia Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Acute Myeloid Leukemia Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Acute Myeloid Leukemia Treatment Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Acute Myeloid Leukemia Treatment Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Acute Myeloid Leukemia Treatment Manufacturer Market Share in 2017
3.3.2 Top 6 Acute Myeloid Leukemia Treatment Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Acute Myeloid Leukemia Treatment Market Analysis by Regions
4.1 Global Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Acute Myeloid Leukemia Treatment Sales and Market Share by Regions (2013-2018)
4.1.2 Global Acute Myeloid Leukemia Treatment Revenue and Market Share by Regions (2013-2018)
4.2 North America Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
4.3 Europe Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
4.5 South America Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
5 North America Acute Myeloid Leukemia Treatment by Countries
5.1 North America Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Countries
5.1.1 North America Acute Myeloid Leukemia Treatment Sales and Market Share by Countries (2013-2018)
5.1.2 North America Acute Myeloid Leukemia Treatment Revenue and Market Share by Countries (2013-2018)
5.2 United States Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
5.3 Canada Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
5.4 Mexico Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
6 Europe Acute Myeloid Leukemia Treatment by Countries
6.1 Europe Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Countries
6.1.1 Europe Acute Myeloid Leukemia Treatment Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Acute Myeloid Leukemia Treatment Revenue and Market Share by Countries (2013-2018)
6.2 Germany Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
6.3 UK Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
6.4 France Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
6.5 Russia Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
6.6 Italy Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
7 Asia-Pacific Acute Myeloid Leukemia Treatment by Countries
7.1 Asia-Pacific Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Acute Myeloid Leukemia Treatment Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Acute Myeloid Leukemia Treatment Revenue and Market Share by Countries (2013-2018)
7.2 China Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
7.3 Japan Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
7.4 Korea Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
7.5 India Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
8 South America Acute Myeloid Leukemia Treatment by Countries
8.1 South America Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Countries
8.1.1 South America Acute Myeloid Leukemia Treatment Sales and Market Share by Countries (2013-2018)
8.1.2 South America Acute Myeloid Leukemia Treatment Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
8.3 Argentina Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
8.4 Colombia Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
9 Middle East and Africa Acute Myeloid Leukemia Treatment by Countries
9.1 Middle East and Africa Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Acute Myeloid Leukemia Treatment Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Acute Myeloid Leukemia Treatment Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
9.3 UAE Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
9.4 Egypt Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
9.5 Nigeria Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
9.6 South Africa Acute Myeloid Leukemia Treatment Sales and Growth Rate (2013-2018)
10 Global Acute Myeloid Leukemia Treatment Market Segment by Type
10.1 Global Acute Myeloid Leukemia Treatment Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Acute Myeloid Leukemia Treatment Sales and Market Share by Type (2013-2018)
10.1.2 Global Acute Myeloid Leukemia Treatment Revenue and Market Share by Type (2013-2018)
10.2 DC regimen Sales Growth and Price
10.2.1 Global DC regimen Sales Growth (2013-2018)
10.2.2 Global DC regimen Price (2013-2018)
10.3 AVD Regimen Sales Growth and Price
10.3.1 Global AVD Regimen Sales Growth (2013-2018)
10.3.2 Global AVD Regimen Price (2013-2018)
10.4 VCD regimen Sales Growth and Price
10.4.1 Global VCD regimen Sales Growth (2013-2018)
10.4.2 Global VCD regimen Price (2013-2018)
11 Global Acute Myeloid Leukemia Treatment Market Segment by Application
11.1 Global Acute Myeloid Leukemia Treatment Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Clinic Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.1 Global Acute Myeloid Leukemia Treatment Sales, Revenue and Growth Rate (2018-2023)
12.2 Acute Myeloid Leukemia Treatment Market Forecast by Regions (2018-2023)
12.2.1 North America Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.2.2 Europe Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.2.3 Asia-Pacific Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.2.4 South America Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.2.5 Middle East and Africa Acute Myeloid Leukemia Treatment Market Forecast (2018-2023)
12.3 Acute Myeloid Leukemia Treatment Market Forecast by Type (2018-2023)
12.3.1 Global Acute Myeloid Leukemia Treatment Sales Forecast by Type (2018-2023)
12.3.2 Global Acute Myeloid Leukemia Treatment Market Share Forecast by Type (2018-2023)
12.4 Acute Myeloid Leukemia Treatment Market Forecast by Application (2018-2023)
12.4.1 Global Acute Myeloid Leukemia Treatment Sales Forecast by Application (2018-2023)
12.4.2 Global Acute Myeloid Leukemia Treatment Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Acute Myeloid Leukemia Treatment Picture
Table Product Specifications of Acute Myeloid Leukemia Treatment
Figure Global Sales Market Share of Acute Myeloid Leukemia
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
